Peregrine Capital Management LLC Has $8.25 Million Stake in HealthEquity, Inc. (NASDAQ:HQY)

Peregrine Capital Management LLC trimmed its position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 9.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,332 shares of the company's stock after selling 10,050 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.11% of HealthEquity worth $8,248,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Wealthfront Advisers LLC acquired a new stake in HealthEquity during the 4th quarter valued at $10,304,089,000. T. Rowe Price Investment Management Inc. bought a new position in shares of HealthEquity during the fourth quarter worth approximately $78,107,000. Norges Bank acquired a new stake in HealthEquity during the 4th quarter worth approximately $74,701,000. Raymond James Financial Inc. bought a new stake in HealthEquity in the 4th quarter valued at $45,728,000. Finally, Iron Triangle Partners LP bought a new stake in HealthEquity in the 4th quarter valued at $32,202,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at HealthEquity

In other news, Director Jon Kessler sold 134,183 shares of HealthEquity stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $112.08, for a total transaction of $15,039,230.64. Following the sale, the director directly owned 253,510 shares of the company's stock, valued at approximately $28,413,400.80. This trade represents a 34.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total transaction of $446,487.50. Following the sale, the director owned 84,969 shares in the company, valued at approximately $6,597,842.85. This represents a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 304,581 shares of company stock worth $33,664,018 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

HealthEquity Price Performance

HealthEquity stock traded down $1.87 during midday trading on Tuesday, reaching $102.89. The company's stock had a trading volume of 921,212 shares, compared to its average volume of 856,820. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of 0.50. The stock has a market cap of $8.90 billion, a PE ratio of 75.10, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. HealthEquity, Inc. has a 52 week low of $65.01 and a 52 week high of $116.65. The business has a 50-day moving average price of $98.89 and a 200-day moving average price of $98.12.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.16. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. The company had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. During the same period in the previous year, the firm posted $0.80 EPS. On average, sell-side analysts predict that HealthEquity, Inc. will post 2.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. KeyCorp lowered their price target on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Wall Street Zen upgraded shares of HealthEquity from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Bank of America boosted their price target on HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Barrington Research raised their price objective on HealthEquity from $112.00 to $125.00 and gave the stock an "outperform" rating in a research note on Thursday, June 5th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, June 5th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, HealthEquity currently has an average rating of "Buy" and a consensus price target of $118.09.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.